Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.04.23.720309

Organophosphorus pesticide and nerve agent surrogate metabolism by human CYP3A4

Abstract

Of the cytochrome P450 enzymes, CYP3A4 is the most abundant isoform in the human liver, and this enzyme plays a dominant role in the metabolism of a wide range of clinical drugs and xenobiotics. Previous studies have demonstrated that CYP3A4 participates in the oxidative metabolism of several organophosphorus (OP) pesticides involving both thion (P=S) and oxon (P=O) forms. In the present study, we evaluated the capacity of CYP3A4 to metabolize a structurally diverse set of OP compounds using LC-MS/MS methods and assessed their potential to inhibit CYP3A4 activity using previously developed pFlour50 fluorogenic assay. Our results demonstrate that CYP3A4 preferentially metabolizes thions, as compared to oxons, and several OP compounds were also found to inhibit CYP3A4 activity in a time-dependent manner. To gain further mechanistic structural insight into the CYP3A4-OP interactions, molecular docking studies were performed using a crystal structure of CYP3A4 (PDB ID: 3NXU). Linear correlation analysis between in silico parameters like molecular weight or binding energy correlated with experimental data including inhibition data for 10 or 30 minutes or the LC-MS/MS data showing the degradation at 1 or 2 hours showed moderate but significant correlation. Soman surrogate PiMP, and cyclosarin surrogate CMP, were both effectively metabolized by CYP3A4, while docking of these surrogates and authentic agents with CYP3A4 receptor revealed very similar binding poses and interactions. Collectively, these findings highlight the important role of CYP3A4 in OP metabolism and support the potential of integrating experimental and in silico data to predict CYP3A4-mediated metabolism of existing and emerging OP compounds, including those of toxicological and chemical warfare relevance.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Shriwas, P., Noonchester, A. M., Scarpitti, B. T., Revnew, A., Lane, T. R., Ekins, S., Hadad, C. M., McElroy, C. A.. 2026-04-27. Organophosphorus pesticide and nerve agent surrogate metabolism by human CYP3A4. https://doi.org/10.64898/2026.04.23.720309

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A metastable GαS/β-arrestin complex sustains endosomal PTH1R signaling

G protein-coupled receptors (GPCRs) initiate cellular signaling by activating heterotrimeric G proteins at the plasma membrane and are silenced when beta-arrestin binds the phosphorylated receptor, preventing G protein binding. However, many receptors continue to generate cAMP after internalization, even while barr is bound, a paradox that lacked a molecular mechanism in live cells. A direct barrestin1-Gas interface in the PTH1R-barr1-Gas complex has recently been defined structurally, but whether the complex operates in endosomes, and how it behaves there, has not been established. Using intact cells, we examine the assembly at three spatial resolutions. Confocal imaging with a nanobody selective for nucleotide-free Gas places activated Gas, barr, and agonist-occupied PTH1R on the same endosomes. Single-molecule localization microscopy, with illumination modes that separate the plasma membrane from the endosomal membrane in single cells, shows that the agonist recruits Gas and barr at both membranes. FRET, however, reveals a specific interaction only on endosomes, where a Gas inhibitor restricted to that compartment abolishes the sustained cAMP phase without affecting receptor internalization. Weighted-ensemble-enhanced molecular simulations show that the complex is metastable, releasing Gas through a large rigid-body rotation away from barr while barr itself tightens its interactions with the receptor. These findings provide a molecular basis for endosomal Gs/cAMP signaling and open a new avenue for drug development targeting this pathway.

pharmacology and toxicology↗

Advancing AOPs for genotoxicity through quantifying KERs linking DNA alkylation to increase in mutations and chromosome aberrations

Quantitative Adverse Outcome Pathways (qAOPs) help translate mechanistic knowledge into quantitative toxicity predictions; however, their development is constrained by the limited availability and heterogeneity of quantitative data. Here, we investigated the feasibility of developing a qAOP for genotoxicity by modeling quantitative relationships linking DNA alkylation to increased mutations and structural chromosome aberrations through intermediate biological key events (KEs). We compiled and harmonized published concentration-response data from human lymphoblastoid TK6 cells exposed to ethyl methanesulfonate, methyl methanesulfonate, or N-ethyl-N-nitrosourea, covering eight genotoxicity assays representing five KEs with well-established dependencies. We evaluated sources of variability, compared points of departure (PoDs), and quantified relationships between successive events using response-response modeling. Substantial between-study variability could to a limited extent be explained through differences in experimental design while batch effects for individual studies and researchers were substantial. PoD estimates that were calculated from combined results of independent studies with similar experimental design, were often uncertain due to insufficient concentration-response characterization or conflicting results between studies. Nevertheless, response-response modeling suggested a threshold effect for certain key-event relationships (KERs). Specifically, DNA adducts seemed to be triggered at lower concentrations of alkylating agents compared to the subsequent KEs of DNA strand breaks and chromosome aberrations. Furthermore, these fitted response-response models can be used for prediction of downstream KEs from earlier ones. The general approach we developed for BMC analysis followed by response-response modeling is applicable to other AOPs as well. These findings highlight both the feasibility and limitations of using existing data for qAOP development.

pharmacology and toxicology↗

Deoxycholic Acid (DCA) a Secondary Bile Acid, Mitigates Ovariectomy-Induced Bone Loss and promotes Bone Healing: A Novel Candidate for Orthopaedic Applications

Introduction Postmenopausal osteoporosis (PMO) is a metabolic disorder, characterized by accelerated bone loss, gut microbiota (GM) dysbiosis and altered microbial metabolites. Deoxycholic acid (DCA) is a secondary bile acid with an FDA-approved drug status for submental fat treatment in adults; however its effect on bone health remains underexplored. Materials and Methods This study investigated the effects of DCA on bone health using both preclinical animal model of PMO and clinical samples from PMO women. DCA (20 mg/kg) was administered to ovariectomised (OVX) mice for 45 days, and its effects on bone microarchitecture and serum cytokines were analysed. Osteoclastogenesis and osteoblastogenesis were evaluated using murine and human samples. Untargeted and targeted metabolomics analyses were performed using an ultra-high-performance liquid chromatographic system coupled with high-resolution Orbitrap mass spectrometry (HRMS). Secondary analysis of 16S rRNA sequencing data was performed using R programming. Results GM analysis and plasma metabolomics revealed an alteration in bacterial taxa associated with secondary BA synthesis and reduced circulating DCA levels. DCA administration improved impaired trabecular and cortical bone microarchitecture in the OVX mice by inhibiting osteoclastogenesis and enhancing osteoblastogenesis. Moreover, DCA altered circulating osteoclastogenic (IL-6, Il-9, IL-17A, IFN-{gamma}, RANKL) and osteoblastogenic (OPG, TGF-{beta}, IL-10) factors. Mechanically, DCA suppressed osteoclast differentiation and the expression of genes associated with osteoclast formation (NFATC1, NFKB, TRAF6, TREM2, SYNB), fusion (CSF1R, DC-STAMP, CD47), and resorption (CTSK, ATP6VOD1, ATP6VOD2, CAR2, SPP1) in human peripheral blood mononuclear cells (PBMCs), while promoting osteogenic differentiation and matrix mineralization in bone marrow-derived mesenchymal stem cells (BMSCs) from PMO women. Additionally, DCA enhanced the nascent calcium deposition at the fracture site and improved bone healing via inhibiting osteoclastogenesis. Conclusion Overall, reduced DCA availability was associated with PMO, while DCA treatment mitigated OVX-induced bone loss and improved bone healing. This study highlights the therapeutic potential of DCA for maintaining both bone homeostasis in PMO and fracture healing with immense orthopaedic applications.

pharmacology and toxicology↗